AbbVie vs Bristol Myers Squibb
This page provides a neutral comparison of AbbVie and Bristol Myers Squibb, examining their distinct business models, recent financial performance, and current market context. Gain insight into key aspects influencing each company's position within the pharmaceutical industry, presented factually to aid understanding. Educational content, not financial advice.
This page provides a neutral comparison of AbbVie and Bristol Myers Squibb, examining their distinct business models, recent financial performance, and current market context. Gain insight into key as...
Why It's Moving
AbbVie Stock Climbs Amid Positive Pipeline Buzz and Undervaluation Signals Ahead of Earnings
- Phase-3 upadacitinib results showed strong efficacy in atopic dermatitis, bolstering the Rinvoq franchise's long-term growth outlook.
- ABBV-932 bipolar disorder study advanced positively, expanding AbbVie's CNS pipeline and future market potential.
- Growing institutional interest, including Los Angeles Capital's recent accumulation of shares, underscores confidence despite analyst estimate tweaks.
BMY Faces Analyst Warnings of 13% Downside Despite Recent Opdivo Wins and Strong Growth Signals
- Opdivo scored expanded approvals for blood cancers on March 25, boosting shares 2.6% that day and widening its market edge against rivals.
- 2026 proxy touts 2025 feats: Growth Portfolio sales surged 17% to $26.4B with seven $1B+ products, plus early $10B debt paydown.
- Board hiked quarterly dividend to $0.63 per share, payable May 1, marking 16 straight years of increases to reward shareholders.
AbbVie Stock Climbs Amid Positive Pipeline Buzz and Undervaluation Signals Ahead of Earnings
- Phase-3 upadacitinib results showed strong efficacy in atopic dermatitis, bolstering the Rinvoq franchise's long-term growth outlook.
- ABBV-932 bipolar disorder study advanced positively, expanding AbbVie's CNS pipeline and future market potential.
- Growing institutional interest, including Los Angeles Capital's recent accumulation of shares, underscores confidence despite analyst estimate tweaks.
BMY Faces Analyst Warnings of 13% Downside Despite Recent Opdivo Wins and Strong Growth Signals
- Opdivo scored expanded approvals for blood cancers on March 25, boosting shares 2.6% that day and widening its market edge against rivals.
- 2026 proxy touts 2025 feats: Growth Portfolio sales surged 17% to $26.4B with seven $1B+ products, plus early $10B debt paydown.
- Board hiked quarterly dividend to $0.63 per share, payable May 1, marking 16 straight years of increases to reward shareholders.
Investment Analysis
AbbVie
ABBV
Pros
- AbbVie maintains dominant market position in immunology with Skyrizi and Rinvoq driving robust revenue growth.
- Strong balance sheet supports sustained R&D investment and share repurchases amid patent cliffs.
- Humira successors demonstrate high-teens growth potential offsetting legacy product declines.
Considerations
- Ongoing patent expirations for key drugs expose revenue to generic erosion through 2028.
- Regulatory hurdles in obesity portfolio delay potential new growth catalysts.
- High debt levels from past acquisitions elevate financial risk in rising interest environment.
Pros
- Growth products like Eliquis, Reblozyl and Breyanzi deliver strong double-digit sales increases into 2026.
- Attractive 4.5% dividend yield backed by 56-year payment history and recent hikes.
- Pipeline catalysts in 2026 offer substantial upside potential beyond priced-in LOE headwinds.
Considerations
- Legacy portfolio faces 15-17% revenue decline in 2025 from generic competition.
- Loss of exclusivity pressures persist through 2028 with $20-30 billion revenue impact.
- Sell-side consensus holds 'Hold' rating despite recent upgrades amid execution uncertainties.
Related Market Insights
Beyond The Patent Cliff: Pharma's New Growth Engines
Discover how pharma companies like AbbVie thrive beyond patent cliffs with new blockbusters. Explore investment opportunities in resilient drugmakers with strong pipelines. Invest from £1.
Aimee Silverwood | Financial Analyst
August 1, 2025
Pharma Giants: Why Healthcare Stocks Could Weather Any Storm
Invest in Pharma Giants: Discover healthcare stocks offering stability, growth, and recession resistance. Explore innovation & consistent demand in the $1.9T pharma market.
Aimee Silverwood | Financial Analyst
July 25, 2025
The Cancer Treatment Revolution: Why Multiple Myeloma Breakthroughs Matter
Discover breakthrough multiple myeloma treatments. Invest in companies pioneering bispecific antibodies & CAR-T therapies driving the next cancer revolution. Explore the Neme.
Aimee Silverwood | Financial Analyst
July 25, 2025
Related Market Insights
Beyond The Patent Cliff: Pharma's New Growth Engines
Discover how pharma companies like AbbVie thrive beyond patent cliffs with new blockbusters. Explore investment opportunities in resilient drugmakers with strong pipelines. Invest from £1.
Aimee Silverwood | Financial Analyst
August 1, 2025
Pharma Giants: Why Healthcare Stocks Could Weather Any Storm
Invest in Pharma Giants: Discover healthcare stocks offering stability, growth, and recession resistance. Explore innovation & consistent demand in the $1.9T pharma market.
Aimee Silverwood | Financial Analyst
July 25, 2025
The Cancer Treatment Revolution: Why Multiple Myeloma Breakthroughs Matter
Discover breakthrough multiple myeloma treatments. Invest in companies pioneering bispecific antibodies & CAR-T therapies driving the next cancer revolution. Explore the Neme.
Aimee Silverwood | Financial Analyst
July 25, 2025
Corporate Titans: The Art of Building Business Empires Through Strategic Acquisitions
Discover companies like Microsoft & Berkshire Hathaway that master strategic acquisitions to build empires. Invest in these growth titans with Nemo's thematic baskets from $1.
Aimee Silverwood | Financial Analyst
July 25, 2025
AbbVie (ABBV) Next Earnings Date
AbbVie's next earnings report is scheduled for April 24, 2026, which will cover the first quarter of 2026 (Q1 2026). The company will announce its financial results before market open, with analysts currently projecting an EPS of $3.01 for the quarter. This earnings announcement will provide investors with updated guidance and financial performance metrics for the period ending March 31, 2026.
Bristol Myers Squibb (BMY) Next Earnings Date
Bristol Myers Squibb will release its next earnings report on April 30, 2026, covering the first quarter of 2026. Company executives will review the financial results during a conference call beginning at 8:00 a.m. ET on that date. Investors and the public can access a live audio webcast of the call through the company's Investor Relations website, with a replay available approximately three hours after the conclusion.
AbbVie (ABBV) Next Earnings Date
AbbVie's next earnings report is scheduled for April 24, 2026, which will cover the first quarter of 2026 (Q1 2026). The company will announce its financial results before market open, with analysts currently projecting an EPS of $3.01 for the quarter. This earnings announcement will provide investors with updated guidance and financial performance metrics for the period ending March 31, 2026.
Bristol Myers Squibb (BMY) Next Earnings Date
Bristol Myers Squibb will release its next earnings report on April 30, 2026, covering the first quarter of 2026. Company executives will review the financial results during a conference call beginning at 8:00 a.m. ET on that date. Investors and the public can access a live audio webcast of the call through the company's Investor Relations website, with a replay available approximately three hours after the conclusion.
Which Baskets Do They Appear In?
Beyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: August 1, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketEmpire Builders
These companies are led by visionaries who excel at growing through smart acquisitions. Our analysts have carefully selected businesses with proven ability to buy competitors, integrate them successfully, and build lasting market power.
Published: June 17, 2025
Explore BasketWhich Baskets Do They Appear In?
Beyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: August 1, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketEmpire Builders
These companies are led by visionaries who excel at growing through smart acquisitions. Our analysts have carefully selected businesses with proven ability to buy competitors, integrate them successfully, and build lasting market power.
Published: June 17, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketBuy ABBV or BMY in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
